




In-hospital and midterm post-discharge complications of adults hospitalised with respiratory syncytial virus infection in France, 2017–2019: an observational study

Alexandre Descamps ¹, Nezha Lenzi², Florence Galtier^{2,3}, Fabrice Lainé^{2,4}, Zineb Lesieur², Philippe Vanhems^{2,5,6}, Sélilah Amour ^{5,6}, Anne-Sophie L'Honneur⁷, Nadhira Fidouh⁸, Vincent Foulongne⁹, Gisèle Lagathu¹⁰, Xavier Duval^{2,11,12}, Corinne Merle¹³, Bruno Lina¹⁴, Fabrice Carrat¹⁵, Odile Launay^{1,2,17} and Paul Loubet^{2,16,17}, on behalf of the FLUVAC study group

¹Université de Paris, Inserm CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France. ²Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France. ³Inserm CIC 1411, Montpellier University Hospital, Montpellier, France. ⁴Inserm CIC 1414, CHU Rennes, Rennes, France. ⁵Service Hygiène, Epidémiologie, Infectiovigilance et Prévention, Centre Hospitalier Edouard Herriot, Hospices Civils de Lyon, Lyon, France. ⁶CIRI, Centre International de Recherche en Infectiologie (Equipe Laboratoire des Pathogènes Emergents), Université Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Lyon, France. ⁷Service de Virologie, Hôpital Cochin, Paris, France. ⁸Laboratoire de Virologie, Hôpital Bichat, Paris, France. ⁹Service de Virologie, CHU Montpellier, Hôpital Saint Eloi, Montpellier, France. ¹⁰Laboratoire de Virologie, Pôle Microorganismes, CHU Rennes, Rennes, France. ¹¹Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Centre d'Investigation Clinique, Inserm CIC 1425, Paris, France. ¹²Université de Paris, IAME, Inserm, Paris, France. ¹³Infectious Diseases Dept, Montpellier University Hospital, Montpellier, France. ¹⁴Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Centre National de Référence des Virus Respiratoires France Sud, Hôpital de la Croix-Rousse, Lyon, France. ¹⁵Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Assistance Publique Hôpitaux de Paris, Hôpital Saint Antoine, Paris, France. ¹⁶VBMI, Inserm U1047, Dept of Infectious and Tropical Disease, CHU Nîmes, Université de Montpellier, Nîmes, France. ¹⁷Last authors contributed equally to this article.

Corresponding author: Paul Loubet (Paul.LOUBET@chu-nimes.fr)



hospitalisation duration (median stay 8 *versus* 6 days, p<0.001). Anti-influenza therapies were less prescribed among RSV patients than influenza patients (20% *versus* 66%, p<0.001). In-hospital composite outcome was poorer in RSV patients (aPR 1.5, 95% CI 1.1–2.1) than in those hospitalised with influenza. No difference was observed for the post-discharge composite outcome (aPR 1.1, 95% CI 0.8–1.6).

Conclusion RSV infection results in serious respiratory illness, with worse in-hospital outcomes than influenza and with similar midterm post-discharge outcomes.